Analyst firms · Raymond James · TFX
Raymond James TFX price target and rating history
Teleflex Incorporated (TFX) · Health Care
Raymond James rates Teleflex Incorporated (TFX) Outperform with a $128 price target, as of its latest action on Mar 27, 2026. It has published 6 rating actions on TFX since September 2021, including 1 upgrade and 1 downgrade. Across 7 firms with a TFX price target in the last 12 months, the median target is $155. Raymond James's $128 is 17% below that.
- Current rating
- Outperform
- Price target
- $128
- Median target, all firms
- $155
- Actions on TFX
- 6
Raymond James price target on TFX
Every Raymond James rating on TFX
- Mar 27, 2026
- Feb 28, 2025
- Feb 25, 2022
- Feb 23, 2022
- Oct 29, 2021
- Sep 7, 2021
How other firms rate TFX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BofA Securities | Buy | $158 | Sep 28, 2026 |
| UBS | Neutral | $145 | Jul 28, 2026 |
| BMO Capital Markets | Outperform | $159 | Jul 9, 2026 |
| Piper Sandler | Overweight | $160 | Jun 8, 2026 |
| RBC Capital Markets | Outperform | $155 | May 8, 2026 |
| Raymond James | Outperform | $128 | Mar 27, 2026 |
| Needham | Buy | $138 | Jan 27, 2026 |
Questions about Raymond James and TFX
- What is Raymond James's price target for TFX?
- Raymond James's latest stated price target for Teleflex Incorporated (TFX) is $128, from its action on Mar 27, 2026.
- What is Raymond James's rating on TFX?
- Raymond James rates TFX Outperform, a bullish rating, as of Mar 27, 2026.
- When did Raymond James last change its view on TFX?
- On Mar 27, 2026, Raymond James upgrades to Outperform from Mkt Perform, price target $128.
- How does Raymond James's TFX target compare with other analysts?
- Across 7 firms with a TFX price target in the last 12 months, the median target is $155. Raymond James's $128 is 17% below that.
More TFX rating histories
All Raymond James ratingsTFX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.